Equities

Elliptic Laboratories ASA

Elliptic Laboratories ASA

Actions
  • Price (EUR)0.864
  • Today's Change-0.009 / -1.03%
  • Shares traded0.00
  • 1 Year change-37.57%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of NOK
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments113176217
Total Receivables, Net674747
Total Inventory------
Prepaid expenses3.090.060.08
Other current assets, total2.811.781.32
Total current assets186226265
Property, plant & equipment, net202.262.79
Goodwill, net------
Intangibles, net584837
Long term investments------
Note receivable - long term8.865.044.52
Other long term assets000.00
Total assets350349371
LIABILITIES
Accounts payable3.861.673.03
Accrued expenses139.338.42
Notes payable/short-term debt000
Current portion long-term debt/capital leases7.996.186.61
Other current liabilities, total0.0000.00
Total current liabilities251718
Total long term debt186.5211
Total debt261317
Deferred income tax------
Minority interest------
Other liabilities, total----0.00
Total liabilities432429
SHAREHOLDERS EQUITY
Common stock1.051.041.04
Additional paid-in capital355346343
Retained earnings (accumulated deficit)------
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(49)(21)(0.81)
Total equity307326343
Total liabilities & shareholders' equity350349371
Total common shares outstanding105104104
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.